Natalie Gasson

Prof. Natalie Gasson

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Human Movement Science
Verified
Journal Article
Closed access
JPJan P. Piek
Jan P. Piek
LDLisa Dawson
Lisa Dawson
LSLeigh M. Smith
Leigh M. Smith
NGNatalie Gasson
Natalie Gasson

13 November 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LTLakkhina Troeung
Lakkhina Troeung
SESarah J. Egan
Sarah J. Egan
NGNatalie Gasson
Natalie Gasson
Psychopharmacotherapy currently constitutes the first-line treatment for depression and anxiety in Parkinson’s disease (PD) however the efficacy of antidepressant treatments in PD is unclear. Several alternative treatments have been suggested as potentially more viable alternatives including dopamine agonists, repetitive transcranial magnetic stimulation, and cognitive behavioural therapy (CBT). A meta-analysis of randomised placebo-controlled trials for depression and/or anxiety in PD was conducted to systematically examine the efficacy of current treatments for depression and anxiety in PD. Nine trials were included. There was only sufficient data to calculate a pooled effect for antidepressant therapies. The pooled effect of antidepressants for depression in PD was moderate but non-significant (d = .71, 95% CI = −1.33 to 3.08). The secondary effect of antidepressants on anxiety in PD was large but also non-significant (d = 1.13, 95% CI = −.67 to 2.94). Two single-trials of non-pharmacological treatments for depression in PD resulted in significant large effects; Omega-3 supplementation (d = .92, 95% CI = .15 to 1.69) and CBT (d = 1.57, 95% CI = 1.06 to 2.07), and warrant further exploration. There remains a lack of controlled trials for both pharmacological and non-pharmacological treatments for depression and anxiety in PD which limits the conclusions which can be drawn. While the pooled effects of antidepressant therapies in PD were non-significant, the moderate to large magnitude of each pooled effect is promising. Non-pharmacological approaches show potential for depression in PD however more research is required.

1 October 2010 in Human Movement Science
Verified
Journal Article
Closed access
JPJan P. Piek
Jan P. Piek
NBNicholas C. Barrett
Nicholas C. Barrett
LSLeigh M. Smith
Leigh M. Smith
DRDaniela Rigoli
Daniela Rigoli
NGNatalie Gasson
Natalie Gasson

27 January 2014 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
LTLakkhina Troeung
Lakkhina Troeung
SESarah J Egan
Sarah J Egan
NGNatalie Gasson
Natalie Gasson
The aim of this study was to evaluate the efficacy of a group Cognitive Behavioural Therapy (CBT) treatment for depression and anxiety in Parkinson’s disease (PD). A waitlist-controlled trial design was used. Eighteen adults with PD and a comorbid DSM-IV-TR diagnosis of depression and/or anxiety were randomised to either Intervention (8-week group CBT treatment) or Waitlist (8-week clinical monitoring preceding treatment). The Depression, Anxiety, Stress Scale-21 (DASS-21) was the primary outcome. Assessments were completed at Time 1 (pretreatment), Time 2 (posttreatment/post-waitlist) and 1-month and 6-month follow-ups. At Time 2, participants who received CBT reported greater reductions in depression (M change = -2.45) than Waitlist participants (M change = .29) and this effect was large, d = 1.12, p = .011. Large secondary effects on anxiety were also observed for CBT participants, d = .89, p = .025. All treatment gains were maintained and continued to improve during the follow-up period. At 6-month follow-up, significant and large effects were observed for both depression (d = 2.07) and anxiety (d = 2.26). Group CBT appears to be an efficacious treatment approach for depression and anxiety in PD however further controlled trials with larger numbers of participants are required. Australian New Zealand Clinical Trials Registry (Trial ID: ACTRN12610000455066 )

15 July 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BLBlake J. Lawrence
Blake J. Lawrence
NGNatalie Gasson
Natalie Gasson
RKRobert Kane
Robert Kane
RBRomola S. Bucks
Romola S. Bucks
Andrea Mary LoftusAndrea Mary Loftus
Andrea Mary Loftus
This study examined whether activities of daily living (ADL) mediate the relationship between depression and health-related quality of life (HR-QOL) in people with Parkinson's disease (PD). A cross-sectional, correlational research design examined data from 174 participants who completed the Geriatric Depression Scale (GDS-15), Parkinson's Disease Questionnaire-39 (PDQ-39), and Unified Parkinson's Disease Rating Scale-section 2 (UPDRS-section 2 [ADL]). Multiple Regression Analysis (MRA) was used to examine the mediator model. Depression and ADL significantly (p<.001) predicted HR-QOL, and depression significantly (p<.001) predicted ADL. Whilst ADL did not impact on the relationship between depression and HR-QOL, there was a significant (p<.001) indirect effect of depression on HR-QOL via ADL, suggesting both direct and indirect (via ADL) effects of depression on HR-QOL. The magnitude of this effect was moderate (R2 = .13). People with PD who report depression also experience greater difficulty completing ADL, which impacts upon their HR-QOL. It is recommended that clinicians adopt a multidisciplinary approach to care by combining pharmacological treatments with psycho/occupational therapy, thereby alleviating the heterogeneous impact of motor and non-motor symptoms on HR-QOL in people with PD.

1 December 2002 in Human Movement Science
Verified
Journal Article
Closed access
JPJan P Piek
Jan P Piek
NGNatalie Gasson
Natalie Gasson
NBNicholas Barrett
Nicholas Barrett
ICIan Case
Ian Case